Preferred Drug List Changes
The following changes have been made to the Nebraska PDL. Changes are effective January 17, 2025.
| Nebraska PDL Therapeutic Drug Class | Drug Name (Route) | PDL Status before 1/17/25 | PDL status on or after 1/17/25 |
|---|---|---|---|
| ANTIHYPERURICEMICS | PROBENECID / COLCHICINE (ORAL) | Preferred | Non Preferred |
| ANTIPSORIATICS, ORAL | ACITRETIN (ORAL) | Preferred | Non Preferred |
| COLONY STIMULATING FACTORS | FULPHILA (SUBCUTANEOUS) | Non Preferred | Preferred |
| COPD AGENTS | SPIRIVA RESPIMAT (INHALATION) | Non Preferred | Preferred |
| CYTOKINE AND CAM ANTAGONISTS | ADALIMUMAB-ADBM KIT (BI) (INJECTION) (CF) 100 MG/ML | Non Preferred | Preferred |
| CYTOKINE AND CAM ANTAGONISTS | ADALIMUMAB-ADBM KIT (BI) (INJECTION) (CF) 50 MG/ML | Non Preferred | Preferred |
| CYTOKINE AND CAM ANTAGONISTS | ADALIMUMAB-ADBM PEN KIT (BI) (INJECTION) (CF) 100 MG/ML | Non Preferred | Preferred |
| CYTOKINE AND CAM ANTAGONISTS | ADALIMUMAB-ADBM PEN KIT (BI) (INJECTION) (CF) 50 MG/ML | Non Preferred | Preferred |
| CYTOKINE AND CAM ANTAGONISTS | CYLTEZO KIT (INJECTION) (CF) 100 MG/ML | Non Preferred | Preferred |
| CYTOKINE AND CAM ANTAGONISTS | CYLTEZO KIT (INJECTION) (CF) 50 MG/ML | Non Preferred | Preferred |
| CYTOKINE AND CAM ANTAGONISTS | CYLTEZO PEN KIT (INJECTION) (CF) 100 MG/ML | Non Preferred | Preferred |
| CYTOKINE AND CAM ANTAGONISTS | CYLTEZO PEN KIT (INJECTION) (CF) 50 MG/ML | Non Preferred | Preferred |
| GLUCOCORTICOIDS, INHALED | FLUTICASONE HFA (AG) (INHALATION) | Non Preferred | Preferred |
| IDIOPATHIC PULMONARY FIBROSIS | OFEV (ORAL) | Preferred | Non Preferred |
| IMMUNOMODULATORS, ATOPIC DERMATITIS | ADBRY AUTOINJECTOR (SUBCUTANEOUS) | Non Preferred | Preferred |
| MOVEMENT DISORDERS | INGREZZA SPRINKLE (ORAL) | Non Preferred | Preferred |
| NSAIDS | CELECOXIB (AG) (ORAL) | Preferred | Non Preferred |
| ONCOLOGY, ORAL - PROSTATE | XTANDI CAPSULE (ORAL) | Preferred | Non Preferred |
| ONCOLOGY, ORAL - PROSTATE | XTANDI TABLET (ORAL) | Preferred | Non Preferred |
| ONCOLOGY, ORAL - RENAL CELL | EVEROLIMUS TABLET (AFINITOR) (ORAL) | Non Preferred | Preferred |
| ONCOLOGY, ORAL - RENAL CELL | SUNITINIB (ORAL) | Non Preferred | Preferred |
| ONCOLOGY, ORAL - RENAL CELL | SUTENT (ORAL) | Preferred | Non Preferred |
| ONCOLOGY, ORAL - SKIN | ERIVEDGE (ORAL) | Preferred | Non Preferred |
| OTIC ANTIBIOTICS | CIPRODEX (OTIC) | Preferred | Non Preferred |
| SEDATIVE HYPNOTICS | ESZOPICLONE (ORAL) | Non Preferred | Preferred |
| STIMULANTS AND RELATED AGENTS | AMPHETAMINE SALT COMBO ER (ORAL) | Non Preferred | Preferred |
| STIMULANTS AND RELATED AGENTS | LISDEXAMFETAMINE CAPSULE (ORAL) | Non Preferred | Preferred |
| STIMULANTS AND RELATED AGENTS | LISDEXAMFETAMINE CHEWABLE TABLET (ORAL) | Non Preferred | Preferred |